Figure 4

Levels of C6A6 stratified into disease severity and treatment. (A) Levels of C6A6 divided into mild and moderate AD (SCORAD; 0–50), and severe AD (SCORAD; < 50), (B) Levels of C6A6 divided into AD patients’ immunosuppressant treatment (topical calcineurin inhibitors), (C) Levels of C6A6 for mild and moderate AD patients receiving immunosuppressant treatment, (D) Levels of C6A6 for severe AD patients receiving immunosuppressant treatment. Mean with 95% confidence interval. Data was analyzed using an ANCOVA corrected for age. Data are depicted as mean ± 95%CI.